Caremark Rx — Merger or Acquisition (January 2007)
37 slides from Caremark Rx's merger presentation, Jan 31, 2007
Slide 1: The CVS/Caremark Merger is in the Best Interest of Shareholders
1 The CVS/Caremark Merger is in the Best Interest of Shareholders Presentation to ISS January 31, 2007 Filed by Caremark Rx, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and Deemed Filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Caremark Rx, Inc. C
Slide 2: Forward-looking statements
2 This document contains certain forward-looking statements about Caremark and CVS. When used in this document, the words “anticipates”, “may”, “can”, “believes”, “expects”, “projects”, “intends”, “likely”, “will”, “to be” and any similar expressions and any other statements that are not historical
Slide 3: Important Information
3 CVS has filed with the SEC a registration statement on Form S-4 that was declared effective by the SEC on January 19, 2007. This registration statement includes a joint proxy statement/prospectus in connection with the proposed merger. Caremark and CVS urge investors and stockholders to read the j
Slide 4: Caremark Profile
4 Leading pharmaceutical services company providing comprehensive drug benefit services to health plan sponsors and their participants Clients Corporate health plans Managed care organizations and insurance companies Unions Government agencies National Prescription Drug Plan under Medicare Part D YT
Slide 5: Slide 5
Slide 6: Slide 6
Slide 7: Slide 7
Slide 8: Caremark Profile
5 Caremark retail network includes 60,000 pharmacies nationwide Caremark operations – 7 mail pharmacies – 21 specialty pharmacies – 9 customer call centers – 12 client-site pharmacies – Industry’s only FDA regulated repackaging plant 13,000 employees, including 1,300 pharmacists Headquarters Medical
Slide 9: Caremark Services Uniquely Integrated
6 Most comprehensive, highest quality DM programs Industry-leading mail expertise Highly-valued generic substitution programs Broad clinical offerings and analytics capabilities Leader in e-prescribing initiatives Largest provider of premier specialty pharmacy programs A Highly Integrated Offering C
Slide 10: CVS Profile
7 Nation’s largest retail pharmacy with more than 6,200 retail and specialty stores in 43 states. Services CVS/pharmacy stores CVS.com MinuteClinic PharmaCare (PBM, Mail, Specialty services) 170,000 employees, including 20,000 pharmacists 2006 revenue $43.8 billion 2006 prescriptions filled 495 mill
Slide 11: CVS/Caremark Merger Overview
8 February 2007 Corporate: Woonsocket, RI PBM: Nashville, TN 50/50 Split Chairman: Mac Crawford President & CEO: Tom Ryan CFO: Dave Rickard President PBM: Howard McLure CVS (NYSE) CVS/Caremark Corporation CVS/Caremark Merger Overview Expected Closing Headquarters Board Composition Management Team Sy
Slide 12: CVS/Caremark Governance Structure Upon Close
9 Provides for annual election of all directors Will have majority voting provision Separate CEO and Chairman Has stock ownership guidelines for D&O Allows stockholders to ratify auditors CVS/Caremark Governance Structure Upon Close
Slide 13: Merger Developed Through Extensive and Thorough Board Management Process
10 Management discussed combination thoroughly over 12 months Mac Crawford and Tom Ryan began discussing a potential strategic combination in October 2005 The CEOs discussed the potential deal numerous times before 11/1/06 CMX and CVS management met numerous times before 11/1/06 Each company’s board
Slide 14: Caremark Board Considered Consumer Strategy Superior to PBM Combination
11 Financial Significance Strategic Significance Consumer Strategy National Retail Chain PBM Caremark Board Considered Consumer Strategy Superior to PBM Combination (Aug 2006) Low Low High High
Slide 15: CVS/Caremark Merger Capitalizes on Evolving Industry Trends
12 CVS/Caremark Merger Benefit Market Trends CVS/Caremark Merger Capitalizes on Evolving Industry Trends In store enrollment and consultation; Medication Therapy Management Medicare Part D More transparency at point of sale - consumer able to make totally informed decisions Cost Shift to Consumer Re
Slide 16: CVS/Caremark Merger is in Best Interest of Shareholders
13 Financial benefits immediate and concrete High certainty of completion Significant strategic benefits Business opportunity Solid financial position Proven management teams CVS/Caremark Merger Enhances Shareholder Value CVS/Caremark Merger is in Best Interest of Shareholders
Slide 17: CVS/Caremark Merger Enhances Shareholder Value
14 Uniquely positioned to capitalize on trends and better serve customers Will enable creation of differentiated services More effective cost management for payors More access to information and choice for consumers Received necessary regulatory approvals from FTC and SEC Shareholder votes are last
Slide 18: CVS/Caremark Merger Enhances Shareholder Value
15 Substantial FCF will enable flexibility for investments in existing business, strategic opportunities, dividends and share repurchases Solid investment grade credit rating Proven track-records with large scale acquisition integration History of exceeding stated synergies Visionary leadership Clie
Slide 19: Back up for Cost Synergy Calculations
16 Cost Synergies Conservatively estimated Calculated by outside consultant retained by legal counsel Rigorous analysis based on input from both management teams Based on details from customer and client contracts Initial estimate of $400 M Bulk of synergies related to purchasing efficiencies Corpor
Slide 20: Near-Term Revenue Opportunities Unique to CVS/Caremark Combination
17 Incremental opportunities of $800 M to $1 B in 2008 Half from PBM, half from retail Revenue estimates based on market research and PharmaCare-CVS experience Revenue synergy examples: Improved access/services for PBM specialty participants Retail to mail conversion (including in-store pick up) Fro
Slide 21: Integration Planning Underway
18 Teams already engaged in integration planning Scope defined and focused on three areas PBM integration Corporate integration New go-to market products and services Individuals for steering committees, project management and core teams have been established and have kicked off activities Integrati
Slide 22: Caremark Board of Directors Thoroughly Considered Express Proposal
19 Caremark BOD met six times to consider Express proposal 12/18/06, 12/22/06, 12/27/06, 1/3/07, 1/5/07 and 1/24/07 Legal counsel thoroughly reviewed legal aspects numerous times Fiduciary duties and standards under Delaware law Applicable requirements of merger agreement with CVS Potential antitrus
Slide 23: Board Concluded Express Proposal Not in Best Interests of Shareholders
20 No experience with large-scale merger integration Recent integration track-record questionable Limited capital for investment in existing business, strategic opportunities, dividends and share repurchases ESRX recently placed on negative watch by rating agencies Clients overwhelmingly negative Ri
Slide 24: Express Scripts Offer Includes Material Conditions
21 A due diligence review Satisfaction of financing conditions Anti-trust and other regulatory approvals Approval by their own shareholders – a process they have not even begun and, which by their own admission, would prevent their illusory February 13 deadline from even occurring No decline in the
Slide 25: Value of Transactions for Caremark Shareholders
22 * VALUES DO NOT REFLECT CONDITIONALITY AND BUSINESS RISK FACTORS ASSOCIATED WITH ESRX PROPOSAL Value of Value of Calculated as of 1/30/2007 CVS Merger ESRX Proposal Counterparty Stock Price 33.05 $ 69.91 $ Exchange Ratio 1.67 0.426 Implied Value of Stock Consideration 55.19 $ 29.78 $ Value of Div
Slide 26: Incentive Alignment
Incentive Alignment Financial Flexibility Contract Wins/Losses Channel Choice Regulatory Approval Options Backdating Vertical Mergers Destroy Value CVS “makes money when patients and clients spend money” ESRX would have “significant financial flexibility’ “In past 3 years, twice as many MX clients h
Slide 27: CVS/Caremark Merger is in the Best Interests of Shareholders
24 • Immediate and concrete financial benefits • February 2007 close • Significant strategic benefits • Clients supportive • Proven management teams • Highly conditional offer • Financial benefits suspect • Uncertain timing • Lacks strategic rationale • Client attrition • CMX would be 20x the larges
Slide 28: CVS/Caremark Merger is in Best Interest of Shareholders
25 Financial benefits immediate and concrete High certainty of completion Significant strategic benefits Business opportunity Solid financial position Proven management teams CVS/Caremark Merger Enhances Shareholder Value CVS/Caremark Merger is in Best Interest of Shareholders
Slide 29: CVS/pharmacy Caremark
CVS/pharmacy CAREMABK
Slide 30: Caremark's Board members have complied with their fiduciary duties
27 Caremark’s Board members have complied with their fiduciary duties and obligations under Delaware law in considering both the CVS transaction and the Express Scripts proposal. Mac Crawford, as Chairman of the Board, serves at the direction of Caremark’s Board of Directors, and he and the other Bo
Slide 31: Caremark director biographies
28 C. David Brown II , 54, has been a member of the Board of Directors since March 2001. He was the Managing Partner of the Orlando, Florida office of Broad and Cassel, a law firm, from 1989 until March 2000, when he became Chairman of the firm. Harris Diamond , 53, has been a member of the Board of
Slide 32: Caremark director biographies
29 Michael D. Ware , 60, has been a member of the Board of Directors since March 2004. Prior to joining the Company’s Board, Mr. Ware served as a director of AdvancePCS beginning in July 1993, and he was also a member of the Compensation and Audit Committees of AdvancePCS. Mr. Ware is a co-founder o
Slide 33: Caremark director biographies
30 Roger L. Headrick , 69, has been a member of the Board of Directors since September 1996 and was named lead director in February 2004. He is Managing General Partner of HMCH Ventures, a private venture capital investment partnership. Since June 1989, Mr. Headrick has been President and Chief Exec
Slide 34: Caremark director biographies
31 Edwin M. Crawford , 57, was named Chairman of the Board of Directors in December 1998. He has served as Chief Executive Officer and as a director of the Company since March 1998. He also served as President of the Company from March 1998 until May 2000, and, effective March 24, 2004, he re-assume
Slide 35: CVS director biographies
32 David W. Dorman Director since 2006 (Age 53) Mr. Dorman is the retired Chairman of the Board and Chief Executive Officer of AT&T Corporation ("AT&T Corp."). From November 2005 until his retirement in January 2006, Mr. Dorman served as President and a director of AT&T, Inc. (formerly known as SBC
Slide 36: CVS director biographies
33 William H. Joyce Director since 1994 (Age 71) Dr. Joyce has been Chairman of the Board and Chief Executive Officer of Nalco Company, a leading provider of integrated water treatment and process improvement services, chemicals and equipment programs for industrial and institutional applications, f
Slide 37: CVS director biographies
34 Thomas M. Ryan Director since 1996 (Age 54) Mr. Ryan has been President and Chief Executive Officer of CVS Corporation since May 1998 and Chairman of CVS Corporation since April 1999; he has also been President and Chief Executive Officer of CVS Pharmacy, Inc. since 1994. Mr. Ryan is a director o